Latest Research Highlights (UK & EU)

Basic Revia Information

• INN (International Nonproprietary Name): Naltrexone hydrochloride
• Brand Names Available In United Kingdom: Revia (brand discontinued in many regions; generics available), Vivitrol (available as extended‑release injection), generics from Teva/Sandoz/Accord Healthcare
• ATC Code: N07BB04
• Forms & Dosages: Tablet 50 mg oral film‑coated scored; Prolonged‑release injection 380 mg vial for intramuscular use after reconstitution
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription Only (Rx)

What has changed in research and safety monitoring about naltrexone across the UK and EU in recent years?

Randomised trials and registry analyses between 2022 and 2025 emphasise modest but clinically meaningful reductions in heavy‑drinking days for alcohol use disorder and lower opioid relapse rates when naltrexone is combined with psychosocial support.

Safety‑signal reviews reported via MHRA and EMA sources note hepatotoxicity risk at high doses and confirm common mild adverse effects such as nausea, headache and insomnia that match prior data.

Clinical practice in NHS settings shows improved engagement and retention when naltrexone treatment is bundled with structured counselling and digital follow‑up through patient portals.

Both oral 50 mg tablets and the 380 mg intramuscular extended‑release injection are referenced in clinical use, with injectable Vivitrol remaining the available extended‑release product.

Initiation protocols continue to require an opioid‑free interval of seven to ten days to avoid precipitated withdrawal when starting naltrexone.

Comparative registry work in Europe indicates effect sizes are modest but clinically useful when naltrexone is part of a broader psychosocial programme.

Data Table: Recent Trial Summaries

Regulatory Highlight

MHRA and EMA guidance drives UK practice and commissioning decisions.

Vivitrol by Alkermes remains the marketed extended‑release option while Revia branding is often discontinued and generics are more common.

Keyword focus in practice: naltrexone studies UK and naltrexone safety.

Clinical Effectiveness In The UK

How well does naltrexone work for people seen in NHS clinics and community services?

UK observational cohorts and NHS audits from 2022–2025 report that oral naltrexone 50 mg daily reduces craving and heavy‑drinking episodes for many patients with alcohol use disorder when used alongside psychosocial interventions.

For opioid use disorder, oral naltrexone shows benefit in motivated, opioid‑abstinent patients but generally has lower retention than opioid agonist therapies such as methadone or buprenorphine.

NHS outcome summaries cite real‑world challenges including adherence to daily tablets, logistics of liver function monitoring and the need for an opioid‑free interval before initiation.

Patient‑reported outcomes on forums such as Patient.info and NHS discussion pages describe an improved sense of control for some patients, balanced against reports of anxiety, sleep disturbance and appetite loss.

Tables: NHS Outcome Metrics

Practical UK practice points include routine pharmacist counselling at Boots, LloydsPharmacy and others to support adherence, and use of NHS electronic prescriptions and patient portals to schedule reminders and follow‑up.

Combining naltrexone with structured community addiction services and digital reminders improves real‑world outcomes and supports retention.

Indications And Expanded Uses

Who is prescribed naltrexone and for what reasons in the UK?

MHRA and EMA‑aligned approvals focus on relapse prevention in alcohol dependence and use as part of opioid use disorder management following detoxification.

The extended‑release injectable 380 mg IM is used in specific settings where monthly clinic administration is feasible.

Specialist clinics sometimes report off‑label use such as reduction of alcohol craving in binge drinking patterns and adjunctive treatment for certain behavioural addictions, but evidence for these uses is limited.

Initiation protocols consistently emphasise ensuring opioid abstinence for seven to ten days to prevent precipitated withdrawal.

In pregnancy, UK clinics assess risk versus benefit closely and involve obstetric and addiction specialists when considering treatment.

• Indication — Dose — Typical Duration
• Alcohol Dependence — 50 mg daily — Minimum 3–6 months
• Opioid Use Disorder (post‑detox) — 50 mg daily or 380 mg IM monthly — Indefinite with regular reassessment
• Off‑Label Uses — Specialist dosing varies — Evidence limited

UK clinicians favour shared decision‑making, and private clinics may offer injectable Vivitrol programmes where NHS commissioning is unavailable.

Documentation checklist for clinicians should include confirmation of opioid‑free status, baseline liver function tests and documented consent for any off‑label use.

Composition And Brand Landscape

What is inside a tablet and which brands will patients see in pharmacies?

The international nonproprietary name is naltrexone hydrochloride and the ATC code is N07BB04.

Revia was historically sold as 50 mg tablets but the brand is discontinued in many regions and generics supplied by manufacturers such as Teva, Sandoz and Accord Healthcare are predominant.

Vivitrol by Alkermes is the marketed extended‑release 380 mg intramuscular product and remains available.

Tablet composition typically is film‑coated, scored, 50 mg per tablet, while the injection is provided as a powder for reconstitution in a single‑use vial.

• Tablet vs Injection
• Tablet: daily dosing, easier to prescribe in primary care, adherence relies on patient taking pills
• Injection: monthly clinic visit, improved adherence for patients who struggle with daily tablets, higher clinic resource need

Patients commonly ask pharmacists whether brand matters; professionals explain that naltrexone hydrochloride is the active ingredient and generics provide equivalent active therapy.

Contraindications And Special Precautions

Who should not take naltrexone and what checks are essential before starting?

Absolute contraindications include ongoing opioid use or recent opioid withdrawal, acute hepatitis and significant hepatic impairment, and known hypersensitivity to naltrexone or excipients.

Relative contraindications that require close monitoring include moderate hepatic or renal impairment and a history of severe depression or suicidal ideation.

Elderly patients require cautious use with liver and renal monitoring, but routine dose reductions are not mandated—clinical review is essential.

Advise patients that dizziness or somnolence can occur and to avoid driving or hazardous work if symptomatic.

Pharmacists in the UK routinely check prescription records for recent opioid prescriptions and advise on liver function monitoring and Yellow Card reporting for suspected adverse reactions.

Dosage Guidelines

What doses are used and what monitoring is recommended?

Standard adult oral dose is 50 mg once daily for both alcohol and opioid relapse prevention, while the extended‑release intramuscular dose is 380 mg every four weeks.

Initiation requires confirmed opioid abstinence for seven to ten days to reduce the risk of precipitated withdrawal before starting either oral or injectable formulations.

In acute hepatitis or liver failure, naltrexone is not recommended and baseline and periodic liver function tests should be arranged for all patients.

Missed dose advice: take as soon as remembered unless close to next dose; do not double up.

In overdose, seek emergency care and monitor liver function for hepatotoxicity.

Clinicians and pharmacists in the NHS often set up monthly repeats and use the NHS App or SMS reminders to support adherence.

Interactions Overview

Which medicines and substances cause problems with naltrexone?

The principal interaction is with opioids where naltrexone can precipitate withdrawal and block opioid analgesia, so opioids are effectively contraindicated while naltrexone is active.

Other relevant interactions include concurrent hepatotoxic medicines which may increase liver risk, and additive effects with central nervous system depressants.

If opioid analgesia is needed for acute pain, plan non‑opioid alternatives or seek specialist advice because naltrexone will block opioid effects.

Community pharmacists play a key role reconciling over‑the‑counter analgesics and flagging interactions via NHS electronic records.

Patients and clinicians are encouraged to report suspected interactions via the MHRA Yellow Card scheme.

Cultural Perceptions And Patient Habits

What do UK patients usually worry about when offered naltrexone?

Qualitative studies and forum discussions show mixed perceptions: many patients welcome a non‑opioid relapse prevention option while others fear stigma, side effects and uncertainty about monitoring.

Trust in pharmacists and the NHS shapes acceptance with many patients preferring initial counselling at community pharmacies such as Boots, LloydsPharmacy and Superdrug or at local addiction services.

Digital NHS tools including the NHS App, electronic prescriptions and the 111 service are commonly used for queries and follow‑up, and proactive pharmacist contact correlates with better adherence.

Regional policy differences affect access, with free prescriptions in Scotland, Wales and Northern Ireland improving affordability compared with England where prescription charges apply.

• Common Patient Concerns: stigma, side effects, cost, liver monitoring
• Supportive Actions: pharmacist counselling, NHS portal reminders, local support groups

Monthly injections are valued by some patients for convenience and adherence, while others prefer oral tablets to avoid clinic visits.

Availability And Pricing Patterns

How easy is it to get naltrexone in UK pharmacies and what does it cost?

Revia brand tablets are discontinued in many regions and generics from manufacturers such as Teva, Sandoz and Accord Healthcare are widely supplied in community pharmacies.

Vivitrol by Alkermes remains the available extended‑release injectable product and is typically sourced for clinic programmes rather than routine community dispensing.

Commissioning of Vivitrol varies between Integrated Care Boards and private clinics may offer injectable programmes where NHS commissioning is limited.

In our online pharmacy, revia is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

• NHS prescription: covered subject to regional rules and prescription charges in England.
• Private purchase: clinic fees for injections and private prescribing costs apply.

Patients should use MHRA‑licensed online pharmacies and check e‑prescribers to avoid unregulated suppliers.

Comparable Medicines And Preferences

When is naltrexone chosen over other medicines and what are the trade‑offs?

For alcohol dependence, alternatives include disulfiram and acamprosate, while for opioid dependence the main comparators are opioid agonist therapies such as methadone and buprenorphine/Suboxone.

Comparative reviews in UK and EU settings show naltrexone is useful where opioid abstinence has been achieved and where a non‑opioid strategy is preferred, but retention may be lower than with agonist therapies.

In clinical decision‑making within the NHS, cost‑effectiveness, monitoring capacity and likely adherence are central to choosing therapy.

Shared decision‑making should weigh a patient’s ability to attend clinic for injections, preference for oral tablets, and willingness to undergo periodic liver function testing.

FAQ

• Will naltrexone make withdrawal worse?
• Answer: Naltrexone must only be started after confirmed opioid abstinence for seven to ten days to avoid precipitated withdrawal.
• Do I need blood tests?
• Answer: Yes, baseline and periodic liver function tests are recommended because of the risk of hepatotoxicity.
• Can I drive or work on naltrexone?
• Answer: Most patients continue normal activities, but if you feel dizzy or drowsy you should avoid driving and discuss occupational risks with your clinician.
• Which Is Better — Tablet Or Monthly Injection?
• Answer: Both lower relapse risk; choice depends on adherence, clinic access, cost and commissioning; injections (Vivitrol 380 mg) support adherence but require monthly clinic visits.

Decision Tree (brief):

Patients should use NHS electronic records and pharmacy counselling for questions and report adverse effects via the MHRA Yellow Card.

Guidelines For Proper Use

What steps should clinicians and pharmacists follow when starting naltrexone?

Assessment should include a full substance history, baseline liver function tests, confirmation of opioid abstinence for seven to ten days and a discussion of risks, benefits and consent.

Start oral naltrexone 50 mg daily or arrange a 380 mg IM injection if extended‑release is chosen and clinic resources allow.

Follow‑up should include scheduled LFT monitoring, mental‑health screening for depression or suicidal ideation and integration with psychosocial therapies.

Pharmacy counselling in the UK emphasises safety checks for recent opioid prescriptions, pregnancy, liver disease and practical advice on missed doses and side‑effect management.

Clinicians should document baseline tests, the opioid screen and a clear follow‑up plan and remind staff about Yellow Card awareness for adverse‑event reporting.

Delivery Across United Kingdom

Final Notes

Revia (naltrexone hydrochloride) is a valid option for relapse prevention in alcohol dependence and, after detox and opioid abstinence, for opioid relapse prevention.

Pharmacists and prescribers should follow MHRA guidance on contraindications and LFT monitoring and embed treatment within psychosocial support for best outcomes.

When patients have adherence challenges, consider the 380 mg IM option and document all baseline tests and follow‑up plans.

For local queries, use NHS electronic records and pharmacy counselling services to coordinate care and report safety concerns through the MHRA Yellow Card system.